ISRCTN36773557 https://doi.org/10.1186/ISRCTN36773557

# Intravaginal APL202 verus dinoprostone in the induction of labour in multiparous subjects

| Submission date | Recruitment status | [ ] Prospectively registered |
|---|---|---|
| 15/01/2010 | No longer recruiting | [ ] Protocol |
| **Registration date** | **Overall study status** | [ ] Statistical analysis plan |
| 15/01/2010 | Completed | [X] Results |
| **Last Edited** | **Condition category** | [ ] Individual participant data |
| 29/01/2010 | Pregnancy and Childbirth | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Ms Rebecca Scoble

**Contact details**
Alliance Pharmaceuticals Ltd
Avonbridge House
Bath Road
Chippenham
United Kingdom
SN15 2BB
medinfo@alliancepharma.co.uk

## Additional identifiers

**Protocol serial number**
APL202-002

## Study information

**Scientific Title**
A randomised open comparison of intravaginal APL202 (25 µg) followed by 25 µg after 4 and 8 hours versus 3 mg of dinoprostone as a vaginal tablet followed by 3 mg after 6 hours in the induction of labour in multiparous subjects

## Study objectives
The objective of study APL202-002 was to determine the safety and efficacy of APL202 in the induction of labour of multiparous subjects compared with the standard agent currently used for cervical ripening.

The trial was previously registered at Pharmaceutical Industry Clinical Trials Database (ABPI /CMR) - https://www.cmrinteract.com/clintrial/default.htm.

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
South East Multi-centre Research Ethics Committee approved on the 4th November 2004 (ref: 04 /MRE01/45)

## Primary study design
Interventional

## Study design
Randomised open comparative non-inferiority study

## Study type(s)
Treatment

## Health condition(s) or problem(s) studied
Induction of labour - multiparous subjects

## Interventions
This was an open, comparative study to determine the safety and efficacy of APL202 in the induction of labour of multiparous subjects compared with dinoprostone, the standard agent for the induction of labour. Each subject was assigned to receive either:
1. APL202 25 µg intravaginally followed by APL202 25 µg intravaginally after 4 and 8 hours, or
2. Dinoprostone 3 mg intravaginally followed by dinoprostone 3 mg intravaginally after 6 hours

The statistical section of the APL202-002 protocol was amended during the course of the study to note that a two-sided analysis would be performed, in line with revised guidelines from the EMEA (Guideline on the choice of the non-inferiority margin, EMEA).

Subjects were randomised equally to each treatment with 506 subjects scheduled to be recruited in conjunction with the same number of subjects in a parallel study APL202-001 (506 were due to be randomised to each treatment). However, a decision was made in 2006 with the agreement of the ethics and regulatory authorities to pool the data from this study and study APL202-001. This meant that a combined total of 622 subjects, with not more than two-thirds and not less than one-third from either study, were required to be enrolled.

Scientific Contact Details - Lead Principal Investigator:
Mr Andrew Loughney MB BS, B Med Sci, PhD, MRCOG
Consultant Obstetrician and Head of Obstetrics
Women's Services
Royal Victoria Infirmary
Richardson Road

Newcastle upon Tyne, NE1 4LP
United Kingdom

### Intervention Type
Drug

### Phase
Phase III

### Drug/device/biological/vaccine name(s)
APL202, dinoprostone

### Primary outcome(s)
Number of vaginal deliveries within 24 hours of the start of induction

### Key secondary outcome(s)
1. Number of vaginal deliveries within 12 hours of the start of induction
2. Number of caesarean section deliveries
3. Mean induction-delivery interval
4. Distribution of induction-delivery interval
5. Oxytocin augmentation requirement
6. Number of instrument-assisted vaginal deliveries
7. Incidence and mean duration of tachysystole
8. Uterine hyperstimulation with fetal heart rate changes
9. Pyrexia during labour
10. Serious neonatal morbidity or perinatal death
11. Serious maternal morbidity or death

Measured at differing timepoints prior to the discharge of the patients from the hospital after the delivery of the baby.

### Completion date
11/03/2007

## Eligibility

### Key inclusion criteria
1. Subjects, aged 18 years or over, who had at least one previous term pregnancy suitable for induction of labour with prostaglandin cervical ripening agents
2. Pregnancy duration of at least 37 weeks
3. Subjects with an unfavourable cervix defined as a Bishop Score of less than 9
4. Signed informed consent

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group

Adult

### Lower age limit
18 Years

### Sex
Female

### Key exclusion criteria
1. Subjects requiring insulin to control their diabetes. Subjects with controlled Type II or gestational diabetes that do not require insulin may be included.
2. Subjects with a multiple pregnancy
3. Subjects in whom oxytocic drugs are generally contraindicated or where prolonged contractions of the uterus are considered inappropriate, i.e:
3.1. History of caesarean section or major uterine surgery
3.2. Cephalopelvic disproportion
3.3. Foetal malpresentation
3.4. Clinical suspicion or definite evidence of pre-existing foetal distress
3.5. History of difficult labour and/or traumatic delivery
3.6. Grand multiparae with over 5 previous term pregnancy
4. Subjects with an intercurrent vaginal, systemic or ascending infection
5. Subjects with clinical suspicion or definite evidence of placenta praevia or unexplained vaginal bleeding during their pregnancy. Occasional spotting, considered by the investigator to be of no clinical significance concerning the use of cervical ripening agents and having a reasonable explanation (e.g. cervical ectropion, cervical polyps), is not a reason for exclusion.
6. Subjects with active cardiac, pulmonary, renal or hepatic disease
7. Subjects with abruptio placenta. Abruptio placenta in a previous pregnancy is not a reason for exclusion.
8. Subjects with ruptured membranes
9. Subjects with a known allergy to prostaglandins or other constituents of the tablets
10. Subjects with any contraindication to vaginal delivery (e.g. active genital herpes)

### Date of first enrolment
05/01/2005

### Date of final enrolment
11/03/2007

## Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre

**Alliance Pharmaceuticals Ltd**
Chippenham
United Kingdom
SN15 2BB

# Sponsor information

**Organisation**
Alliance Pharmaceuticals Ltd (UK)

**ROR**
https://ror.org/001zd1d95

# Funder(s)

**Funder type**
Industry

**Funder Name**
Alliance Pharmaceuticals Ltd (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

**IPD sharing plan summary**
Not provided at time of registration

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/09/2008 | | Yes | No |